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Abstract
Background: Recipient selection for liver transplantation in hepatocellular carcinoma (HCC) is based primarily on criteria
affecting the chance of long-term success. Here, the relationship between pretransplant bridging therapy and long-term survival was
investigated in a subgroup analysis of the SiLVER Study.
Methods: Response to bridging, as defined by comparison of imaging at the time of listing and post-transplant pathology
report, was categorized into controlled versus progressive disease (more than 20 per cent tumour growth or development of new
lesions).
Results: Of 525 patients with HCC who had liver transplantation, 350 recipients underwent pretransplant bridging therapy. Tumour
progression despite bridging was an independent risk factor affecting overall survival (hazard ratio 1.80; P¼ 0.005). For patients
within the Milan criteria (MC) at listing, mean overall survival was longer for those with controlled versus progressive disease
(6.8 versus 5.8 years; P< 0.001). Importantly, patients with HCCs outside the MC that were downsized to within the MC before liver
transplantation had poor outcomes compared with patients who never exceeded the MC (mean overall survival 6.2 versus 6.6 years
respectively; P¼ 0.030).
Conclusion: Patients with HCCs within the MC that did not show tumour progression under locoregional therapy had the best
outcomes after liver transplantation. Downstaging into the limits of the MC did not improve the probability of survival.
Prognostic factors determining the long-term success of liver transplantation in patients with hepatocellular carcinoma are still un-
der discussion. A subgroup analysis of the SiLVER trial showed that disease control under bridging therapy is strongly associated
with improved prognosis in terms of overall survival. However, in tumours exceeding the limits of the Milan criteria, downstaging
did not restore the probability of survival compared with that of patients within the Milan criteria.
Introduction
Tailored therapy based on individual patient and tumour factors
is a goal of cancer management1. Hepatocellular carcinoma
(HCC) is treated by different therapeutic means, but the bench-
mark algorithm is the Barcelona Clinic Liver Cancer system2,3.
For HCC in liver transplant (LTx) recipients, guidance for patient
selection is provided by the Milan criteria (MC), which define a
subset of patients with favourable prognosis (single HCC lesions
up to 5 cm in size or 1–3 lesions up to 3 cm, no extrahepatic mani-
festations, no macroscopic vascular invasion)4. Using patient eli-
gibility based on the MC has substantially improved survival
rates after LTx, producing results similar to those for patients
with non-tumour indications5. However, categorizing patients
with HCC solely based on tumour volume does not always result
in accurate risk stratification for post-transplant disease-free
(DFS) or overall (OS) survival. To address this issue, examining tu-
mour growth and biology may reveal factors that more reliably
predict HCC recurrence after LTx. Indeed, diagnostic tools to
stratify post-LTx cancer risk at the time of HCC diagnosis are con-
tinuing to be refined6. For example, specific biomarkers (such as
a-fetoprotein, AFP) may help to predict poor outcome in HCC7,
but a reliable classification system based on such parameters is
still lacking.
Apart from molecular or histopathological cancer features,
simple cancer progression itself may represent a predictor of
poor biological behaviour. In this regard, many patients with
HCC on the waiting list for LTx undergo routine locoregional
treat-and-wait testing, which may be regarded as an in situ
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functional test predicting the biological aggressiveness of each
person’s cancer8. Previous studies have postulated that patients
with HCC initially outside the MC that is downstaged successfully
to within the MC have a prognosis similar to that of patients who
were always within the MC9. Consequently, current United
Network for Organ Sharing (UNOS) guidelines support a down-
staging protocol (from outside to inside the MC), which focuses
on response to bridging therapy, and an interval between bridging
and transplantation10. Prospective data to validate this concept
are lacking. The aim of the present study was to analyse bridging
therapy in relation to tumour size and number on outcome after
LTx.
Methods
Data from the SiLVER study (Sirolimus in Liver Transplant
Recipients with HCC study, NCT00355862) were used as a basis
for this analysis11. The SiLVER study was a prospective random-
ized trial conducted in 13 European, Canadian, and Australian
LTx centres, with the aim of testing whether mTOR inhibition
could improve outcomes in patients receiving a LTx for HCC. For
the purpose of the present subgroup analysis, only complete data
sets from patients receiving locoregional HCC bridging treatment
were included. Regarding HCC metrics, two sets of data were in-
cluded in the analysis of each patient from the electronic case re-
port system. The first set (pre-LTx) comprised the number and
diameter of lesions determined by standard imaging techniques
at the time of listing, and the second set (at the time of LTx) con-
sisted of tumour data from the histopathology report obtained
from the explanted liver. In accordance with Response
Evaluation Criteria In Solid Tumours (RECIST)12, HCCs were de-
fined as progressive if the sum of the tumour diameter(s) after
LTx exceeded the pre-LTx sum by 20 per cent or more. HCCs with
a change in tumour load of less than a 20 per cent increase at the
time of LTx represented controlled disease.
Statistical analysis
Continuous data are shown as mean(s.d.). The probability of sur-
vival was modelled by Kaplan–Meier analysis, with differences
evaluated using the log rank test, and Cox regression analysis
in SPSS version 25 (IBM, Armonk, New York, USA). Two-tailed
P < 0.050 was considered statistically significant.
Results
Of 525 patients in the SiLVER study, 350 underwent one or more
HCC bridging treatments. Median follow-up was 5.3 (i.q.r. lower
quartile: 2.4 years; upper quartile: 6.2 years) years. Bridging ther-
apy consisted mainly of transarterial chemotherapy (47.1 per
cent), radiofrequency ablation (19.1 per cent), and surgical resec-
tion (5.4 per cent) (Table 1). Mean(s.d.) age of the cohort was
57.8(7.0 years), and most of the study subjects were men (87.7 per
cent). Mean time on the waiting list was 222 days, with a maxi-
mum of 7.25 years. Most tumours were smaller than 3 cm (58.3
per cent at time of listing), with the majority of the patients (51.7
per cent) presenting with single lesions. Approximately two-
thirds of the patients had HCCs within the MC at the time of list-
ing (68.3 per cent; detected by imaging) and transplantation (63.1
per cent; based on explant pathology report).
Multivariable analysis of disease-free and overall
survival
The variables age, time on the waiting list, AFP level before LTx,
Milan status at listing (based on imaging), and tumour progression
were included in a multivariable Cox regression analysis to deter-
mine their influence on DFS and OS in the bridging therapy sub-
group. Although time on the waiting list and AFP level before LTx
did not significantly affect survival, tumour progression was signif-
icantly associated with worse DFS (HR 1.50, 95 per cent c.i. 1.03 to
2.20; P¼ 0.035) and OS (HR 1.80,1.20 to 2.71; P¼ 0.005) (Table 2).
Tumours outside the MC at listing were significantly associated
with decreased DFS (HR 1.69, 1.15 to 2.47; P¼ 0.007), but only
approached the threshold for significance regarding OS in this co-
hort.
Hepatocellular carcinoma progression and Milan
criteria status
Tumour progression during bridging and the overall tumour load
(MC status at listing) were separated into two subgroups for
Table 1 Demographics, bridging therapy, and tumour data
Listing (imaging) Explant histology
No. of patients 350
Age (years)* 57.8(7.0)
Sex ratio (m : f) 307 : 43
Time on waiting list (days)* 222(306)








0 0 (0) 61 (17.4)
1 181 (51.7) 134 (38.3)
2 69 (19.7) 60 (17.1)
3 49 (14.0) 42 (12.0)
4–5 41 (11.7) 28 (8.0)
> 5 10 (2.9) 25 (7.1)
Size of largest nodule (cm)
No tumour 0 (0) 61 (17.4)
< 3.0 204 (58.3) 115 (32.9)
3.0–5.0 118 (33.7) 131 (37.4)
5.1–7.5 22 (6.3) 30 (8.6)
> 7.5 6 (1.7) 13 (3.7)
Within Milan criteria 239 (68.3) 221 (63.1)
Values in parentheses are percentages unless indicated otherwise; * values are
mean(s.d.). † Data available for 349 patients. AFP, a-fetoprotein; LTx, liver
transplantation; TACE, transcatheter arterial chemoembolization; RFA,
radiofrequency ablation.
Table 2 Results of multivariable Cox regression analysis
Disease-free survival Overall survival
Hazard ratio P Hazard ratio P
Age (per year) 1.04 (1.01, 1.07) 0.011 1.05 (1.02, 1.08) 0.003
Time on waiting list 1.00 (1.00,1.00) 0.137 1.00 (1.00, 1.00) 0.213
AFP before LTx 1.00 (1.00, 1.00) 0.815 1.00 (1.00, 1.00) 0.809
P
rogression
1.50 (1.03, 2.20) 0.035 1.80 (1.20, 2.71) 0.005
Outside Milan
at listing
1.69 (1.15, 2.47) 0.007 1.45 (0.96, 2.19) 0.081
Values in parentheses are 95 per cent confidence intervals. AFP, a-fetoprotein;
LTx, liver transplantation.
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further survival modelling (Fig. 1). Mean DFS was 6.5 (95 per cent
c.i. 6.1 to 6.9) years in the subgroup inside the MC with controlled
tumour growth, compared with 5.5 (4.9 to 6.2) years in the sub-
group with tumour progression (P¼ 0.002) (Fig. 1a). In the sub-
group with disease outside the MC, no difference in DFS was
noted between patients with controlled or progressive disease
(Fig. 1b). Similar results were observed for OS. Patients initially in-
side the MC had significantly better mean OS when bridging
resulted in no tumour progression (6.8 (6.4 to 7.1) years; 5-year
survival 82.2 per cent) than in those with disease progression (5.8
(5.1 to 6.4) years; 5-year survival 65 per cent) (P< 0.001) (Fig. 1c).
Response to bridging therapy in patients outside the MC did not
affect OS; mean survival was 6.2 (5.5 to 7.0) years in patients with
controlled disease versus 5.4 (4.6 to 6.2) years in those with pro-
gressive disease (P¼ 0.726) (Fig. 1d).
To analyse whether patients were affected negatively by tu-
mour progression, even if the tumours stayed within the limits of
imaging-based MC before LTx, 55 patients on bridging therapy
who went from inside to outside the MC were excluded during
the waiting period for LTx. In a subsequent analysis including
only disease that stayed within the MC, patients with tumour
progression during bridging had decreased DFS (mean 5.5 (4.5 to
6.5) versus 6.5 (6.1 to 6.9) years; P¼ 0.089) and significantly worse
OS (5.5 (4.5 to 6.5) versus 6.8 (6.4 to 7.1) years; P¼ 0.021) than
patients whose HCC was controlled during bridging therapy
(Fig. 2).
Downstaging in patients originally outside the
Milan criteria
Patients were categorized according to Milan status before and
after bridging therapy (at listing (imaging) and at LTx (pathol-
ogy)). In terms of DFS and OS, 184 patients who remained inside
the MC throughout the LTx waiting period had significantly bet-
ter outcomes than all other subgroups (Fig. 3). Thirty-seven
patients with successful downstaging (out-to-in subgroup) had a
mean DFS of 4.7 (95 per cent c.i. 3.7 to 5.6) years and OS of 6.2 (5.0
to 7.3) years, whereas patients who remained within the limits of
the MC had superior survival, with mean DFS and OS of 6.3 (5.9 to
6.7) years (P¼ 0.008) and 6.6 (6.2 to 6.9) years (P¼ 0.030) respec-
tively. The 5-year survival rate (OS) was 79.5 per cent in patients
with HCC never exceeding the MC, compared with 61 per cent
among those with disease downstaged from outside the MC.
Discussion
As long as LTx is the only curative therapy for HCC in patients
with cirrhosis, the question of patient selection will be an impor-
tant matter for discussion13. The internationally applied (and
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Fig. 1 Kaplan–Meier estimates of disease-free and overall survival for patients with hepatocellular carcinoma within or outside the Milan criteria at
listing based on imaging
Disease-free survival for patients a within and b outside the Milan criteria (MC), and overall survival for patients c within and d outside the MC. a P ¼ 0.002, b P ¼
0.490, c P < 0.001, d P ¼ 0.726 (log rank test).
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often critiqued) MC allow definition of a subset of patients who
benefit from LTx in terms of DFS and OS. Results from the pre-
sent analysis of the SiLVER study are in line with predictions
from the MC. However, the MC use a static tumour size/number
evaluation and do not consider tumour progression during the
LTx waiting period. The hypothesis related to this analysis was
that tumour progression under the pressure of bridging therapy
(ablate and wait8) before LTx may also be relevant to DFS and OS.
Indeed, the present results showed that tumour progression is an
independent risk factor for disease recurrence and mortality.
Moreover, small (within the MC) but growing tumours that
remained within the MC by the time of LTx were associated with
outcomes similar to those for patients with disease outside the
MC. This observation underscores the need for a comprehensive
view of HCC lesions, including both growth dynamics and tumour
load. Although a few small trials have suggested a predictive
value of response to bridging before transplantation14,15, the
SiLVER study provides a relatively large data set to demonstrate
its association with DFS and OS, especially in the setting
of small tumours. This is also consistent with a large US
registry study16 that showed increasing AFP levels in patients un-
dergoing locoregional therapy to be an indicator of relatively poor
prognosis.
Another important aspect of the analysis was investigation
of the effect of downstaging in patients with high-risk tumours
(outside the MC before bridging). Some studies12,17 have sug-
gested that reducing tumour volume with bridging therapy to
within the limits of the MC allows LTx with a prognosis similar
to that for patients within the MC. Recently, Kardashian and
colleagues18 reported OS rates as high as 64.3 per cent in
patients with downstaged tumours compared with 71.3 per
cent for those within the MC, thereby underscoring the poten-
tial benefits of successful downstaging. In the SiLVER study co-
hort, downstaging from outside to within the MC resulted in
100
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b Disease-free survival: outside MC
Fig. 3 Kaplan–Meier model of disease-free and overall survival, according to behaviour of lesions during bridging/time on waiting list
a Disease-free and b overall survival in relation to changes in Milan criteria status during therapy assessed by comparing listing imaging and explant
histopathology. In, disease within limits of Milan criteria; out, disease outside limits of Milan criteria. a P < 0.050 (remaining in versus other subgroups; b P ¼ 0.068
(remaining in versus remaining out), P < 0.050 (remaining in versus in-to-out and out-to-in subgroups) (log rank test).
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Fig. 2 Effect of progression during bridging on disease-free and overall survival in patients with hepatocellular carcinoma within the Milan criteria
both at the time of listing and at transplantation
a Disease-free and b overall survival. a P ¼ 0.089, b P ¼ 0.021 (log rank test).
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distinctively worse outcomes than those for patients who
remained within the MC, an observation shared by others19,20.
Further refinement of selection criteria for patients with down-
staged disease, for example by including AFP levels or waiting
time21, may contribute to improved survival rates. However,
without an RCT specifically addressing this issue, the present
results suggest that considerable caution should be exercised
when expecting that HCC downsizing will achieve expected
outcomes.
The SiLVER study was neither powered nor initially designed to
answer these questions, so limitations should be considered regard-
ing the present analysis. First, bridging modalities were not stan-
dardized, and varied in both technique and frequency between
study participants. Data acquisition was also limited by the fact
that only consistently documented data for imaging at the time of
diagnosis and in pathology reports from explanted livers post-LTx
were available. Therefore, there was no planned interim analysis of
tumour responses during bridging treatment, limiting knowledge
about tumour kinetics and responses to therapy before LTx.
Furthermore, patient enrolment into the SiLVER study was started
in 2006, years before the introduction of the modified RECIST crite-
ria, which would have allowed a more subtle analysis of tumour
load and behaviour. This issue was addressed by introducing a sim-
plified, but yet reliable categorization scheme (within versus outside
the MC, controlled versus progressive tumour). It is also worth
noting that the study protocol did not require (at that time) a wait-
ing period between bridging and transplantation, as demanded by
current UNOS criteria for patients with downstaged HCC.
Overall, this analysis has highlighted the potential negative
prognostic impact of tumour progression in patients with HCC re-
ceiving locoregional therapy before LTx. The present results high-
light the need for prospective trials that are specifically designed
to assess HCC progression under pressure from bridging therapy,
before making the critical decision regarding how to best to use
organs for LTx.
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